Understanding the genetic basis of hereditary diffuse gastric cancer

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

An­ti­body-drug con­ju­gate (AD­Cs) man­u­fac­tur­ing is like­ly to re­main among CD­MOs al­ready mak­ing them due to de­mand­ing mar­ket en­try re­quire­ments, ex­ec­u­tives in the ADC space said.

Af­ter sev­en months on the mar­ket, Re­gen­eron’s Eylea HD is al­ready mak­ing strides with oph­thal­mol­o­gists. Ac­cord­ing to Spher­ix Glob­al In­sights’ re­search, 81% of oph­thal­mol­o­gists who